The veterinary-grade API designated Ivermectin (Ivomec) is not a single chemical species but a defined mixture of two homologous macrocyclic lactones. The principal component, 22,23-dihydroavermectin B1a, has empirical formula C48H74O14 and molecular weight 875.1 g/mol; the minor component, 22,23-dihydroavermectin B1b, has empirical formula C47H72O14 and molecular weight 861.1 g/mol. The mixed entity is registered under CAS 70288-86-7. The structural relationship to abamectin is a selective saturation of the C22-C23 double bond, and the resulting hydrogenated system is the pharmacological basis of the Ivomec parasiticidal line. Compendial descriptions in Ph Eur 2176 and the corresponding USP monograph define the substance through chromatographic resolution and control of the H2B1a/H2B1b ratio rather than through a single molecular formula. This distinction is operationally important because a certificate of analysis that reports only total assay may conceal an abnormal homologue ratio that alters potency in target species.
Because the API is practically insoluble in water and freely soluble only in select organic solvents such as ethanol and methanol, process selection depends heavily on the intended dosage form. For tablets, capsules, powders, granules, and premixes, dissolution testing must be carried out in surfactant-containing media because plain aqueous buffers do not provide sink conditions. For injectable solutions, the API is dissolved in a non-aqueous or water-miscible vehicle, and residual moisture in both the API and the vehicle becomes a critical stability parameter. The product model specification must therefore state the intended route: a micronized tablet grade, a low-endotoxin injection grade, or a premix grade suitable for carrier dispersion. Purchase specifications that omit this route designation may pass pharmacopoeial release testing but still fail during downstream processing.
What compendial tests control the veterinary API grade?
The API is released against Ph Eur 2176 or the current USP monograph, with the HPLC assay quantifying the sum of H2B1a plus H2B1b. The acceptance range is generally not less than 95.0% and not more than 102.0% on the dried basis, with system suitability requiring baseline resolution of the H2B1a and H2B1b peaks before any batch is approved. Identification is confirmed by infrared absorption spectrophotometry according to Ph Eur 2.2.24 and by HPLC retention time against a reference standard. Related substances are monitored by gradient reversed-phase HPLC; the most relevant separations are between the two homologues, residual abamectin-type unsaturation products, and late-eluting hydrogenation by-products. Residual solvent compliance follows ICH Q3C or VICH GL18; methanol, where used in purification, is controlled under the ICH Q3C class 2 limit of 3000 ppm, while ethanol and other class 3 solvents are controlled to the conventional 5000 ppm limit. For non-sterile solid oral and premix grades, total aerobic microbial count is controlled to not more than 10³ CFU/g and total combined yeasts and moulds to not more than 10² CFU/g, with absence of Escherichia coli evaluated according to Ph Eur 5.1.4 or USP <61> as applicable. Parenteral grade requires an endotoxin specification derived from the finished product dose; where the maximum daily dose justifies it, an API limit of not more than 0.05 EU/mg is used.
Pharmacopoeial compliance establishes chemical acceptability but not processability. The conversion of a low-dose hydrophobic API into solid oral dosage forms depends on particle-size distribution, agglomerate strength, and surface energy. Production-scale experience on rotary tablet presses fitted with force feeders has shown that unmilled ivermectin with a median particle size above 30 µm segregates during feed frame transfer and produces superpotent or subpotent tablets even when the average blend assay is within specification. The same phenomenon is observed in low-energy tumble blenders when the API is added late to a coarse filler without geometric dilution. Content uniformity failures in tablets and capsules are therefore more commonly caused by particle segregation than by chemical degradation.
For tablets and capsules, the API is typically processed through a spiral jet mill to a target D90 of not more than 25 µm and a D50 of not more than 10 µm as measured by laser diffraction per ISO 13320:2020. The micronized material is pre-blended with a portion of lactose monohydrate or microcrystalline cellulose and passed through a 500 µm screen before the main blending step. Final content uniformity is assessed according to Ph Eur 2.9.40 or USP <905>; acceptance values below the compendial L1 limit of 15 are normally expected for validated batches. Compression runs are typically performed on rotary presses with force feeder speed adjusted to prevent powder bed depletion; tablet hardness is controlled primarily by the filler-binder matrix because the API rarely exceeds 2% w/w of the core. Over-lubrication with magnesium stearate above 1.0% w/w or prolonged high-shear mixing beyond 15 minutes reduces aqueous wetting and slows dissolution of the hydrophobic API.
| Finished dosage form | Typical particle-size or solvent target | Production equipment | Critical control point |
|---|---|---|---|
| Tablets / capsules | D90 ≤ 25 µm | spiral jet mill, tumble blender, rotary press with force feeder | content uniformity per Ph Eur 2.9.40 / USP <905> |
| Injections | dissolved in non-aqueous vehicle; D90 not applicable | 0.22 µm sterilizing filter | endotoxin and residual moisture control |
| Powders / premixes | D90 ≤ 150 µm after geometric dilution | ribbon mixer or plough mixer | assay homogeneity across sampling points |
| Granules | D90 ≤ 50 µm before granulation | fluid-bed granulator, top spray | final granule moisture not more than 2.0% w/w |
Where the dose is delivered as a medicated powder, granule, or feed premix, the API is not compressed but dispersed by stepwise geometric dilution onto a carrier. Ribbon mixers and plough mixers with working volumes between 500 L and 2000 L are representative for production-scale premix manufacture. Ground corn cobs, wheat middlings, and lactose monohydrate are used as carriers with particle diameters generally between 150 µm and 800 µm. The API is first pre-mixed with 5–10 kg of carrier per 1000 kg of total batch and passed through a screening mill before addition to the main mixer. Batch uniformity failures on production lines are more frequently observed as stratified superpotent or subpotent zones within the mixer rather than as total batch assay failure. The premix is sampled according to a statistically valid plan, and the relative standard deviation of the mean assay across sampling points should not exceed 5.0%. Granules may be produced by fluid-bed granulation with inlet air temperature controlled between 50 °C and 70 °C; after drying, the granules are milled through a 1000 µm screen and blended with extragranular disintegrant where immediate release is required.
Injectable solvent systems and sterile filtration bottlenecks
Injectable ivermectin formulations, including the 1% w/v non-aqueous product, typically use glycerol formal and propylene glycol as the primary solvent system. The API is fully dissolved rather than suspended, so particle-size limits are replaced by raw-material water content and pre-filtration bioburden. Residual moisture in the API for parenteral use is generally controlled to not more than 0.5% w/w because water can hydrolyze the macrocyclic lactone ring and reduce assay during storage. The drug solution is sterilized by filtration through a 0.22 µm membrane because terminal steam sterilization may accelerate oxidative darkening and increase related substances. On high-viscosity non-aqueous lines, filtration capacity is limited by the pressure differential across the membrane; a rise from 0.5 bar to 2.0 bar within a single batch indicates viscosity-related fouling or particulate load and requires filter replacement. Pre-filtration bioburden should be maintained at not more than 10 CFU/100 mL to avoid exceeding the retention capacity of the sterilizing-grade membrane. The dissolution of the API in the vehicle should be performed below 60 °C with controlled mixing because prolonged heating can raise the related substance profile.
When abamectin, doramectin, or eprinomectin are evaluated as direct substitutes
Ivermectin differs structurally from abamectin primarily by saturation of the C22-C23 double bond; abamectin retains the unsaturated parent system and carries a distinct toxicological and residue profile in cattle, sheep, and swine. Doramectin and eprinomectin possess additional structural modifications that alter tissue distribution and milk residue depletion, so their maximum residue limits and withdrawal periods are not interchangeable with ivermectin under Commission Regulation (EU) No 37/2010 or corresponding national requirements. A formulation change from ivermectin to another macrocyclic lactone requires revalidation of the manufacturing process, stability protocol, and target-species residue depletion because the active entity is not a simple equivalent. Published data for direct substitution across all species and formulations is limited; regulatory dossiers generally require separate bioequivalence or residue depletion studies. Within the ivermectin family, the veterinary API grade is further distinguished from human-formulation API by VICH GMP documentation, residue-control obligations, and route-specific microbial or endotoxin specifications. The chemical entity may be identical when both meet the same pharmacopoeial monograph, but the release requirements and regulatory status are not automatically harmonized.
Stability of the veterinary API is adequate when the material is stored in tight, light-resistant containers at controlled room temperature and protected from moisture. Strongly acidic excipients, oxidizing agents, and free water should be avoided because they accelerate degradation of the macrocyclic lactone ring. For bulk storage, polyethylene-lined fibre drums with desiccant are preferred. Processing batches should not be held in open containers at high relative humidity because the hydrophobic powder can adsorb fines and moisture, altering flow and agglomeration behaviour. Where a formulation contains acidic vehicles or hygroscopic excipients, compatibility studies should include assay and related substance testing rather than appearance alone. The data required for a finished product registration must be developed for the specific route, species, and dose, and cannot be transferred from a different macrocyclic lactone without controlled comparative evidence.
